Investor Relations

Press Releases

 
Press Releases
  Date Title and Summary View
Dec 7, 2017
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"), today announced the pricing of an underwritten public offering of 5,338,709 shares of its ...
Dec 5, 2017
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"), today announced a proposed underwritten public offering in which it will issue and sell ...
Dec 5, 2017
- Highly statistically significant results on primary composite endpoint achieved at Week 4 - - RT002 delivered highly statistically significant reduction in severity of glabellar lines at Week 24 - - If approved, RT002 could represent a new, next-generation, long-acting ...
Nov 29, 2017
- Company completes End-of-Phase 2 Meeting with FDA - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced the completion of its End-of-Phase 2...
Nov 20, 2017
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions, today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for the Company's ...
Nov 2, 2017
-SAKURA 1 & 2 Phase 3 pivotal trials on track to report topline results before year-end 2017- -SAKURA 3 open-label safety study for glabellar lines has completed enrollment of more than 2,100 subjects- NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NAS...
Oct 18, 2017
- Conference Call Scheduled for Thursday, November 2, 2017 at 4:30pm ET - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that th...
Oct 18, 2017
- Company expects to report topline eight-week results at the end of the year - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions, today ann...
Sep 19, 2017
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in the Cantor Fitzgerald 2017 Global Healthcare Conference in New York, NY. ...
Sep 6, 2017
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions, today announced that Mark Foley has been appointed to Revance's Board of Directors, effective September 5, 2017. ...
Page:
1
... NextLast
= add release to Briefcase
Shareholder Tools